Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes

Journal of Clinical Lipidology

Volumn 2, Issue 1, 2008, Pages 25-35

  Weinstock, Ruth S ^a   Goldberg, Ronald B ^b   Guyton, John R ^c   Mazzone, Theodore ^d   Polis, Adam ^e   Tomassini, Joanne E ^e   Lin, Jianxin ^e   Shah, Arvind ^e   Tershakovec, Andrew M ^e  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ApoB; Atorvastatin; Ezetimibe simvastatin; Hs CRP; LDL C; Non HDL C

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT CARE; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 39149117012     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.01.001     Document Type: Article

References (34)

1. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 suppl 1 (2006) S4-S42
2. Solano M.P., and Goldberg R.B. Dyslipidemia and diabetes. Cardiol Rev 14 (2006) 125-135
3. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 13 (2004) 227-239
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 105 (2002) 3143-3421
6. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
7. Collins R., Armitage J., Parish S., Sleight P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
8. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
9. Maki K.C., Galant R., and Davidson M.H. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol 96 9A (2005) 59K-64K
10. Chan D.C., and Watts G.F. Apolipoproteins as markers and managers of coronary heart disease. QJM 99 (2006) 277-287
11. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2526-2529
12. Clarenbach J.J., Grundy S.M., Palacio N., and Vega G.L. Relationship of apolipoprotein B levels to the number of risk factors for metabolic syndrome. J Invest Med 55 (2007) 237-247
13. Stein E.A., Sniderman A., and Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96 9A (2005) 36K-43K
14. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
15. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
16. Genest J., Frohlich J., Fodor G., and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 (2003) 921-924
17. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice-a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
18. Best L.G., Zhang Y., Lee E.T., et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes-The Strong Heart Study. Circulation 112 (2005) 1289-1295
19. Goldberg R.B., Guyton J.R., Mazzone T., et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 81 (2006) 1579-1588
20. Liu J., Sempos C., Donahue R.P., Dorn J., Trevisan M., and Grundy S.M. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 28 (2005) 1916-1921
21. Jiang R., Schulze M.B., Li T.C., et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27 (2004) 1991-1997
22. Lu W., Resnick H.E., Jablonski K.A., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes-The Strong Heart Study. Diabetes Care 26 (2003) 16-23
23. Pischon T., Girman C.J., Sacks F.M., Rifai N., Stampfer M.J., and Rimm E.B. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
24. Ballantyne C.M., Bertolami M., Hernandez Garcia H.R., et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II. Am Heart J 151 (2006) 975-979
25. Grundy S.M., Hansen B., Smith Jr. S.C., Cleeman J.I., and Kahn R.A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109 (2004) 551-556
26. Rizzo M., Rini G.B., and Berneis K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther 24 (2007) 575-582
27. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., and Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88 (2001) 265-269
28. Ridker P.M., Rifai N., Cook N.R., Bradwin G., and Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
29. Sniderman A.D., St-Pierre A.C., Cantin B., Dagenais G.R., Despres J.P., and Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91 (2003) 1173-1177
30. LeRoux G., Lemieux I., Lamarche B., et al. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism 49 (2000) 53-61
31. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/1-an analysis of the PROVE-IT TIMI-22 trial. JAMA 45 (2005) 1618-1644
32. Simon A., Chironi G., Gariepy J., Del Pino M., and Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 179 (2005) 339-344
33. Cui Y., Blumenthal R.S., Flaws J.A., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161 (2001) 1413-1419
34. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein-A meta-analysis. J Am Coll Cardiol 49 (2007) 2003-2009